By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NewBridge Pharmaceuticals 

One Embarcadero Center
Suite 2700
San Francisco  California  34111-3776  U.S.A.
Phone: 415-591-5483 Fax: 415-591-5483


Company News
Eisai Inc. (ESALF.PK) Announces Partnership With NewBridge Pharmaceuticals To Market Breast Cancer Treatment Halaven® (Eribulin) Across The Middle East 11/18/2013 9:13:09 AM
NewBridge Pharmaceuticals to Commercialize the verifi® Prenatal Test 2/15/2013 8:38:45 AM
NewBridge Pharmaceuticals Forms Partnership With Genomic Health, Inc. to Bring Novel Genomic Testing to Patients in Middle East, Africa, and Caspian Regions 8/13/2012 8:54:40 AM
NewBridge Pharmaceuticals Signs Agreement for Abstral(TM) for the Middle East and Africa 9/22/2010 10:10:50 AM
NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments Including New CEO 9/21/2010 6:43:18 AM
Orexo AB Signs Agreement for Abstral(TM) for the Middle East and Africa 9/16/2010 10:23:28 AM
NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 7/22/2009 8:58:11 AM
NewBridge Pharmaceuticals Announces Exclusive Licensing of Clasteon and Gliconorm for Middle East, Africa, Turkey and Caspian Regions 11/25/2008 12:40:24 PM